Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Midatech Pharma Plc | Amryt Pharmaceuticals | Ergomed Plc | Avacta Group Plc | Alliance Pharma plc

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.


This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


The event is not suitable for people pursuing commercial opportunities.


Alliance Pharma plc

RSS Portfolio


Alliance is an international publicly owned pharmaceutical group listed on AIM, part of the London Stock Exchange. It was founded in 1998 and has its headquarters in the UK.

Alliance's principal activities are the acquisition and licensing of mature pharmaceutical products and the marketing of those products. Its manufacturing, storage, logistics and sales forces are controlled by Alliance but outsourced to leading specialist organisations in these fields.

Market: AIM
52-week High/Low: 53.50p / 40.50p
Market Cap: 224.58M

View full company profile

Amryt Pharmaceuticals

RSS Portfolio


Amryt Pharma is a specialty pharmaceutical company focused on the developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

Market: AIM
52-week High/Low: 27.95p / 13.44p
Market Cap: 50.00M

View full company profile

Avacta Group Plc

RSS Portfolio


Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in diagnostics, therapeutics and research.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer proteins, which can be quickly generated to bind with high specificity and affinity to a wide range of targets, have been designed to address these negative performance issues. 

Avacta has a pre-clinical drug development programme with a primary focus on immuno-oncology as well as partnered development programmes. Avacta is also commercialising non-therapeutic Affimer reagents through licensing to developers of research tools and diagnostics.

Market: AIM
52-week High/Low: 113.00p / 60.00p
Market Cap: 61.21M

View full company profile

Ergomed Plc

RSS Portfolio


Founded in 1997, Ergomed plc is a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. It operates globally in over 40 countries.

Ergomed plc has two complementary businesses:
(1) The Services Business – a well-established, clinical research business providing services to the pharmaceutical and biotechnology industry; and
(2) The Co-Development Business – a growing portfolio of partnerships with pharmaceutical and biotech companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including outlicensing milestones as well as sales of the product

Market: AIM
52-week High/Low: 216.88p / 117.00p
Market Cap: 80.81M

View full company profile

Midatech Pharma Plc

RSS Portfolio


Midatech is an international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas.


Market: AIM
52-week High/Low: 189.90p / 100.51p
Market Cap: 57.22M

View full company profile

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use